Home
    Disclaimer

    Tilmetamine Stats & Data

    Psychoactive Class Dissociative
    Half-Life Unknown in humans; no published PK. Some users report prolonged after‑effects inconsistent with short elimination, suggesting either active metabolites or non‑PK mechanisms.

    Effect Profile

    Curated
    Dissociative 6.0

    Strong dissociative depth and motor impairment with mild mania, low insight

    Dissociative Depth×3
    10
    Mania / Compulsion×1
    4
    Insight / Novel Thought×2
    3
    Motor / Sensory Impairment×1
    10

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown in humans; no published PK. Some users report prolonged after‑effects inconsistent with short elimination, suggesting either active metabolites or non‑PK mechanisms.
    Addiction Potential
    Unknown. Community reports indicate binge/compulsive redosing patterns similar to other arylcyclohexylamines, with very rapid tolerance development; however, unusually severe adverse after‑effects appear to discourage continued use for many.

    Tolerance Decay

    Full tolerance 3d Half tolerance 14d Baseline ~42d

    Rapid tolerance buildup is frequently reported with arylcyclohexylamines; figures are qualitative and based on community patterns rather than formal PK. Space sessions by several weeks to reduce risk of lingering adverse effects.

    Cross-Tolerances

    Ketamine
    60% ●○○
    Tiletamine
    60% ●○○
    PCP analogs
    50% ●○○

    Harm Reduction

    drugs.wiki

    Extremely limited formal data exist; nearly all information comes from user reports. Many users report active insufflated doses in the single‑digit to low‑tens of milligrams, indicating very high potency; this makes microgram‑accurate weighing and preferably volumetric dosing essential to avoid accidental overdosing. Supply‑side confusion between tilmetamine and tiletamine has been frequently discussed; at least one set of lab results confirmed high‑purity tilmetamine in two separate samples, yet users still described starkly different effect profiles, so mislabeling cannot alone explain all adverse reactions—expect idiosyncratic responses. Redosing during the same day or on consecutive days is repeatedly associated with markedly worse and longer‑lasting adverse effects (notably whole‑body tremor, fine‑motor impairment, and vestibular disturbances), sometimes lasting days to weeks; avoid binges and space trials by at least several weeks. Several reports describe exacerbation of tremor/anxiety when combined with serotonergic medications (SSRIs, buspirone) or taken while recently on them; given the unknown pharmacology, treat serotonergic co‑use as a risk factor and avoid combinations. People have reported prolonged disequilibrium and vision/focus issues (e.g., delayed accommodation, visual static) that impair driving and fine tasks—do not drive for at least 24–48 hours after moderate–high use and until fully normal. If considering injection routes, be aware that small parenteral doses produced disproportionately strong effects in reports; due to unknown excipients, sterility risks, and the potential for severe neurologic after‑effects, IM/IV use is strongly discouraged outside clinical settings. Use GC/MS‑based drug checking where available to confirm identity and assess purity; reagent kits are of limited value for arylcyclohexylamines and cannot ensure safety. Store in airtight, light‑protected containers with desiccant to limit potential oxidative degradation of sulfur‑containing analogs; avoid heat. In an emergency (severe agitation, psychosis, chest pain, intractable vomiting, or disabling tremor/vertigo), seek medical care; do not attempt to self‑treat with random prescriptions (especially antipsychotics), and disclose that an unknown dissociative may have been used.

    ← Back to Tilmetamine